PD-L1 expression on tumor-infiltrating ICs was prospectively determined by immunohistochemistry, and all the patients were categorized into in three different groups based on percentage of PD-L1-positive ICs: IC0 (<1% expression), IC1 (≥1%, but ≤5% expression), and IC2/3 (≥5% expression). The gene discussed is CD274; the disease is neoplasm.